DelveInsight Business Research LLP
Albany, NY -- (SBWIRE) -- 08/30/2018 -- Uveal melanoma is the most common intraocular malignancy and arises from melanocytes in the iris (anterior), ciliary body, or choroid (posterior). Iris melanomas have the best prognosis, whereas melanomas of the ciliary body have the least favourable prognosis. Most uveal tract melanomas originate in the choroid while the iris is the least common. The typical choroidal melanoma is a brown, elevated, dome-shaped sub retinal mass. The degree of pigmentation ranges from dark brown to totally amelanotic. Melanomas of the choroid generally are more malignant. Males have a higher incidence than females. UM is diagnosed mostly at older ages, with a progressively rising, age-specific, incidence rate that peaks near the age of 70 years. Most Uveal melanomas are initially completely asymptomatic. As the tumour enlarges, it may cause distortion of the pupil (iris melanoma), blurred vision (Ciliary body melanoma), or markedly decreased visual acuity caused by secondary retinal detachment (choroidal melanoma). Serous detachment of the retina may occur.
According to the report of DelveInsight "Uveal Melanoma (UM) Market Insights, Epidemiology and Market Forecast-2027" UM is the most common primary intraocular malignancy in adults which represents 3%–5% of all melanomas. UM is clinically and biologically different from cutaneous melanoma. Metastasis frequently occurs in this disease, and once distant spread occurs, outcomes are poor. The mean age-adjusted incidence of Uveal Melanoma in the United States is approximately 4.3 new cases per million people, with no clear variation by latitude. Ocular melanoma rates are 8-10 times higher among whites compared with blacks. The number of new melanoma cases are estimated to be 3,540, out of which 350 died from cancer of eyes and orbit in US.
Market Outlook of Uveal Melanoma Market
The current market of Uveal Melanoma consists of primary global-preserving therapies like surgery, laser or photocoagulation or trans pupillary thermotherapy, Plaque brachytherapy, charged particle therapy, ionizing radiation, stereotactic radiotherapy. Despite of its effective primary therapy, nearly 50% of patients develop metastatic disease and it remains unclear what effect they have on patient survival rate. The current treatment of Metastatic Uveal Melanoma is limited by the lack of effective systemic therapy. The options for the treatment of the primary intraocular tumour include radical surgery as well as enucleation in order to preserve visual acuity. Conventional systemic chemotherapy has shown poor response rates in Uveal Melanoma as the disease is resistant to these conventional systemic therapies. Currently, there is no approved treatment for metastatic UM. Several palliative treatments for UM offered in the US and Europe include Liver-directed treatments-Trans arterial Catheter and Immunotherapy, targeted therapy.
Emerging Drugs Analysis
Key players such as AstraZeneca, Delcath Systems Inc., Pfizer, Aura Biosciences, BioMed Valley Discoveries, Immunocore Ltd and many others are involved in developing the treatment therapies for Uveal Melanoma. Expected launch of emerging therapies such as Selumetinib in combination with Dacarbazine (AstraZeneca), Melphalan (Delcath Systems Inc), IMCgp100 (in combination with Dacarbazine, Ipilimumab, and Pembrolizumab) (Immunocore Ltd), Crizotinib (Pfizer), Light-activated AU-011 (Aura Biosciences), BVD-523 (BioMed Valley Discoveries, Inc) and other compelling treatments, are expected to impact the overall market size of Uveal Melanoma during the study period 2016-2027.
The report covers the descriptive overview of Uveal Melanoma explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. The report provides the insight into the epidemiology of the disease and its treatment in the 7 MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape. The report also reviews the detailed historical and forecasted Uveal Melanoma market size covering the drug outreach in 7MM. The report provides the understanding of the future competition in Uveal Melanoma by reviewing the market drivers and barriers.
For Sample Report: https://www.delveinsight.com/report-store/uveal-melanoma-market-insight-epidemiology-and-market-forecast
Reasons to buy:
1. The report will help in developing business strategies by understanding trends shaping and driving the Uveal Melanoma market.
2. To understand the future market competition in the Uveal Melanoma market and Insight reviews of the key market drivers and barriers.
3. Identification of strong upcoming players in the Uveal Melanoma market will help in devising strategies that will help in getting ahead of competitors.
4. In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.
2.Delcath Systems Inc.
5.BioMed Valley Discoveries
And many others……………
Table of Contents
1. Report Introduction
2. Uveal Melanoma Market Overview at a Glance
3. Disease Background and Overview: Uveal Melanoma
4. Epidemiology and Patient Population
5. Uveal Melanoma: Country- Wise Epidemiology
5.1. United States
6. Treatment & Medical Practices
7. Emerging Therapies
8. 7MM Uveal Melanoma: Country-Wise Market Analysis
8.1. United States
8.4. United Kingdom
9. Report Methodology
10. DelveInsight Capabilities
*** For detailed TOC request for sample pages.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses
We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.